Evidence map›Paper›PMID 31164324›Full record

ArticleEuropean urology oncology2019

Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications.

Mohammed Alshalalfa, Paul L Nguyen, Himisha Beltran, William S Chen, Elai Davicioni, Shuang G Zhao, Timothy R Rebbeck, Edward M Schaeffer, Tamara L Lotan, Felix Y Feng and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Neuropeptide Y as a Neuro-Immune Checkpoint in Cancer.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Neuropeptide Y Peptide Family and Cancer: Antitumor Therapeutic Strategies.International journal of molecular sciences · 2023
    Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Mohammed AlshalalfaHelen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA, USA; Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA. Electronic address: mohamed.alshalalfa@gmail.com.
Paul L NguyenDana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA.
Himisha BeltranDana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA.
William S ChenHelen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA, USA.
Elai DavicioniGenomeDx Biosciences Inc, Vancouver, British Columbia, Canada.
Shuang G ZhaoDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Timothy R RebbeckDana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA.
Edward M SchaefferDepartment of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Tamara L LotanDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Felix Y FengHelen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA, USA; Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA; Department of Urology, University of California San Francisco, San Francisco, CA, USA.
Brandon A MahalDana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA, USA.
Brigham and Women's Hospital · USUCSF Helen Diller Family Comprehensive Cancer Center · USDana-Farber Brigham Cancer Center · USGenome British Columbia · CAJohns Hopkins University · USNorthwestern University · USUniversity of Michigan–Ann Arbor · US

Funding

Precision Interception of Aggressive Prostate Cancer in African American MenP20CA233255 · NCI · DANA-FARBER CANCER INST · PI REBBECK, TIMOTHY R · 2018 to 2020
$3.2M
NCI NIH HHS P20 CA233255
6 · The paper itself

Abstract

backgroundTumor microenvironment and its interaction with neuroendocrine modulators contribute to prostate carcinogenesis and progression.

objectiveWe sought to define the transcriptomic and clinical implications of neuropeptide Y (NPY) expression in prostate cancer progression. DESIGN, SETTING, AND

participantsGenome-wide expression profiling of three localized prostate cancer (total n=18818) and five metastatic castrate-resistant prostate cancer (mCRPC; total n=495) cohorts was used to characterize NPY expression. All men underwent radical prostatectomy (RP) for localized prostate cancer. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patients were grouped into those with low NPY and high NPY based on NPY expression. Associations between these groups and histological, genomic, and clinical outcomes including progression-free survival (PFS) and metastases-free survival (MFS) were examined. Combining ERG-fusion status with NPY expression, four groups were defined (lowNPY/ERG+, lowNPY/ERG-, highNPY/ERG+, and highNPY/ERG-). Cox proportional hazards modeled the time to distant metastasis after RP. Genomic risk scores for metastasis were calculated for prospective samples, based on a 22-gene signature. RESULTS AND LIMITATIONS: Across cancers, NPY showed the highest expression in prostate cancer in The Cancer Genome Atlas (TCGA) PAN-Cancer cohort (n=9483, p<0.0001). In 17967 prospective samples, low NPY expression was associated with aggressive grade group 5 disease and a higher genomic risk (p<0.0001). In the retrospective (n=355) and TCGA (n=497) cohorts, low NPY was associated with shorter MFS and PFS, respectively (p=0.001 for both). In mCRPC cohorts, low NPY was associated with neuroendocrine development (p<0.01). NPY was highly correlated to ERG; thus, we defined four groups based on NPY expression and ERG fusion. The lowNPY/ERG+ subtype was associated with the highest genomic risk for metastasis (p<0.0001) and the highest rate of metastasis compared with all other subtypes (hazard ratio [HR]: 2.2 [1.22-4.03], p=0.008), while the highNPY/ERG- subtype was associated with the lowest genomic risk for metastasis (p<0.0001) and the lowest rate of metastasis (HR: 0.53 [0.35-0.81], p=0.003).

conclusionsLow NPY expression is associated with adverse genomic features and clinical correlates and outcomes. The lowNPY/ERG+ subtype was associated with the highest risk of developing metastasis. Prognostic subgrouping and tailored treatments by NPY expression and ERG fusion status warrant further study. PATIENT SUMMARY: The low neuropeptide Y prostate cancer subtype appears to be aggressive with a high risk of developing metastasis.

Indexed as

Disease ProgressionHumansKaplan-Meier EstimateMaleNeuropeptide YProgression-Free SurvivalProportional Hazards ModelsProstatic NeoplasmsTranscriptional Regulator ERGTranscriptomeERG protein, humanNeuropeptide YTranscriptional Regulator ERGARERGNPYProstate

Identifiers

PMID31164324
PMCPMC7597937
OpenAlexW2947253482

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.